Vaccines and melanoma
Author:
- 1 October 2002
- journal article
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 27 (7) , 597-601
Abstract
Melanoma is one of the prototypic immunogenic tumors. Various immunotherapeutic approaches for melanoma have been developed in the past decades. Recent scientific progress includes the discovery of defined melanoma antigens, new tools for monitoring of an anti-cancer immune response and application of novel adjuvants for amplification of the immune response such as dendritic cells. These and other advances in the field of melanoma vaccines will be discussed.Keywords
This publication has 17 references indexed in Scilit:
- Dendritic cells: On the move from bench to bedsideNature Medicine, 2001
- High-Dose Interferon Alfa-2b Significantly Prolongs Relapse-Free and Overall Survival Compared With the GM2-KLH/QS-21 Vaccine in Patients With Resected Stage IIB-III Melanoma: Results of Intergroup Trial E1694/S9512/C509801Journal of Clinical Oncology, 2001
- Progress in human tumour immunology and immunotherapyNature, 2001
- IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicityNature, 2001
- Autologous, hapten-modified vaccine as a treatment for human cancersVaccine, 2001
- Cell-based vaccination against melanoma – background, preliminary results, and perspectiveJournal of Molecular Medicine, 1999
- Adjuvant therapy of melanomaSeminars in Surgical Oncology, 1998
- Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cellsNature Medicine, 1998
- Tumor antigens recognized by T lymphocytesInternational Journal of Clinical and Laboratory Research, 1997
- Development of Cancer Immunotherapies Based on Identification of the Genes Encoding Cancer Regression AntigensJNCI: Journal of the National Cancer Institute, 1996